KROS News and Press, Keros Therapeutics Inc. From 03/25/21

LEXINGTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffer...

Keros Therapeutics (KROS) announces results from preclinical studies of KER-050 and its ALK2 inhibitor program at the virtual European School of Haematology held from March 5 through 7, 2021. Keros has previously shown that mice treated with a single 10 mg/kg dose of a research form of KER-05...

LEXINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffer...

LEXINGTON, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musc...

LEXINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

Keros Therapeutics, a clinical stage biopharmaceutical company with no close-to-market product in its three-candidate pipeline, has seen a stupendous rally in its stock price. KROS is currently focused on less frequently occurring diseases, with its lead candidate KER-050 targeting th...

LEXINGTON, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

LEXINGTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...

P resentation highlight s data from Keros’ Phase 1 clinical trial of KER-047 , which demonstrat ed r obust and sustained dose-related increases in serum iron and transferrin saturation that were associated with decreases in ferritin and hepcidi...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...